Literature DB >> 11295576

Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study.

J Jimenez1, S R Kapadia, M H Yamani, L Platt, R E Hobbs, G Rincon, C Botts-Silverman, R C Starling, J B Young, S E Nissen, M Tuzcu, N B Ratliff.   

Abstract

Intravascular ultrasound (IVUS) is established as the optimal method for early detection of transplant vasculopathy. The association between cellular rejection and development of transplant vasculopathy remains controversial. This study attempts to determine the rate of progression of transplant vasculopathy lesions and its relationship with cellular rejection in a long-term (> 1 year) IVUS serial follow-up.A study cohort of 47 patients undergoing heart transplantation from 1993 to 1995 was evaluated. Intravascular ultrasound was performed at baseline (within 8 weeks) and annually for a period of 3 years to determine maximum intimal thickness and maximum plaque area in each coronary segment. Significant allograft vasculopathy was defined as a site with intimal thickness > 0.5 mm not present at baseline. Biopsy results were scored by assigning a numerical weight to each ISHLT grade during the first year. Donor lesions ranged from 0.86 to 1.1 mm, showing no evidence of progression at serial follow-up. De novo lesions were identified in 30 patients. These lesions appeared yearly but progressed slowly. The average biopsy score in the entire cohort was 1.1 +/- 0.8. Average biopsy score was > 1.0 in 35 patients with significant linear correlation between the rate of intimal progression and biopsy score (r = 0.42, p = 0.01). Multivariate analysis demonstrated that only the biopsy score correlated with the rate of progression. Lesions of donor atherosclerosis do not change significantly after transplantation. However, de novo lesions continue to develop every year. In patients with evidence of rejection, the rate of progression of transplant vasculopathy correlates with the severity of rejection.

Entities:  

Mesh:

Year:  2001        PMID: 11295576     DOI: 10.1016/s1053-2498(00)00249-7

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

Review 1.  Mechanisms of chronic rejection in cardiothoracic transplantation.

Authors:  Matthew J Weiss; Joren C Madsen; Bruce R Rosengard; James S Allan
Journal:  Front Biosci       Date:  2008-01-01

2.  Cellular and Functional Imaging of Cardiac Transplant Rejection.

Authors:  Yijen L Wu; Qing Ye; Chien Ho
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-02-01

Review 3.  Cardiac allograft vasculopathy: the Achilles' heel of long-term survival after cardiac transplantation.

Authors:  Amandeep Dhaliwal; Vinay Thohan
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

4.  Combined heart and liver transplant attenuates cardiac allograft vasculopathy compared with isolated heart transplantation.

Authors:  Yan Topilsky; Eugenia Raichlin; Tal Hasin; Barry A Boilson; John A Schirger; Naveen L Pereira; Brooks S Edwards; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Manish J Gandhi; Simon Maltais; Soon J Park; Richard C Daly; Amir Lerman; Sudhir S Kushwaha
Journal:  Transplantation       Date:  2013-03-27       Impact factor: 4.939

5.  Management of the Patient After Heart Transplant.

Authors:  Michael A Mathier; Dennis M McNamara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-12

6.  Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation.

Authors:  Giuseppe Vassalli; Giuseppina Milano; Tiziano Moccetti
Journal:  J Transplant       Date:  2012-03-18

7.  Diagnostic performance of late gadolinium enhancement in the assessment of acute cellular rejection after heart transplantation.

Authors:  Evrim Şimşek; Sanem Nalbantgil; Naim Ceylan; Mehdi Zoghi; Hatice Soner Kemal; Çağatay Engin; Tahir Yağdı; Mustafa Özbaran
Journal:  Anatol J Cardiol       Date:  2015-06-18       Impact factor: 1.596

8.  CXCR4 Antagonist Reduced the Incidence of Acute Rejection and Controlled Cardiac Allograft Vasculopathy in a Swine Heart Transplant Model Receiving a Mycophenolate-based Immunosuppressive Regimen.

Authors:  Wan-Tseng Hsu; Cheng-Hsin Lin; Hsiang-Yiang Jui; Ya-Hsuan Tseng; Chia-Tung Shun; Ming-Chu Hsu; Kenneth Kun-Yu Wu; Chii-Ming Lee
Journal:  Transplantation       Date:  2018-12       Impact factor: 4.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.